secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K/A
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001104659-24-112975
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX corrects FY24 comparable margin expansion to 30-60 bps (from 70-100 bps); Q3 EPS $2.80
--------------------------------------------------------------------------------

- Corrected 2024 comparable operating profit margin expansion to 30-60 bps from 70-100 bps (error in prior release).
- Q3 revenue $976M (+7% reported, +6% organic); CAG Diagnostics recurring revenue +7%.
- Q3 diluted EPS $2.80, +11% as reported, +12% comparable basis; operating margin 31.2%.
- Updated FY24 revenue guidance to $3.865B-$3.890B (~1% lower at midpoint); EPS narrowed to $10.37-$10.53.
- FY24 organic revenue growth now 5.3%-6.0% (prior 6.2%-7.8%) due to softer U.S. clinic visit trends.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465924112975/0001104659-24-112975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465924112975/tm2427217d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer